IP Library Granted Patent US 11,850,232
Granted Patent B2
US 11,850,232 · App. 17/106,862 · Granted Dec 26, 2023

Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug

Inventors: Teiji Tominaga (Sendai, JP); Kuniyasu Niizuma (Sendai, JP)
Assignee: BIOGEN MA INC.
A61K31/407A61P7/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,850,232
App. No.
17/106,862
Granted
Dec 26, 2023
Kind
B2
Abstract

A drug used for treating or preventing cerebral hemorrhage, the drug including, as an active ingredient, a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof:

Claims (7)

1. A method of treating a cerebral hemorrhage in a subject in need of, comprising administering SMTP-7 or a pharmaceutically acceptable salt thereof, in an amount effective for treating the cerebral hemorrhage, to the subject suffering from the cerebral hemorrhage, wherein the method reduces or eliminates a hematoma, an edema, or both a hematoma and an edema, and wherein treating the cerebral hemorrhage is independent of treating a cerebral infarction.

2. The method according to claim 1 , wherein the cerebral hemorrhage is intracerebral hemorrhage.

3. The method according to claim 1 , wherein SMTP-7 or a pharmaceutically acceptable salt thereof is administered intracerebrally.

4. The method according to claim 1 , wherein the method reduces or eliminates a hematoma.

5. The method according to claim 1 , wherein the method reduces or eliminates an edema.

6. The method according to claim 1 , wherein the method reduces or eliminates both a hematoma and an edema.

7. The method according to claim 1 , wherein the cerebral hemorrhage does not associate with a cerebral infarction.

Assignments (4)
CHANGE OF NAME Recorded Dec 4, 2024
From: JI XING PHARMACEUTICALS HONG KONG LIMITED
To: CORXEL PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 069492/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2024
From: BIOGEN MA INC.
To: JI XING PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 066379/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2022
From: TMS CO., LTD.
To: BIOGEN MA INC.
Reel/Frame 059527/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2021
From: TOMINAGA, TEIJI; NIIZUMA, KUNIYASU
To: TMS CO., LTD.
Reel/Frame 055438/0575 →
Priority Claims (1)
JP 2019-209932 · Nov 20, 2019 · national
Continuity (1)
Related Publication 20210322381A1 · Oct 21, 2021
Cited By (1)
US 12,453,718